

## company announcement

## Novo Nordisk A/S – Share repurchase programme

**Bagsværd, Denmark, 13 October 2014** – On 7 August 2014, Novo Nordisk initiated a share repurchase programme in accordance with the provisions of the European Commission's regulation no 2273/2003 of 22 December 2003, also referred to as the Safe Harbour rules. This programme is part of the overall share repurchase programme of up to DKK 15.0 billion to be executed during a 12-month period beginning 30 January 2014.

Under the programme initiated 7 August 2014, Novo Nordisk will repurchase B shares for an amount up to DKK 3.5 billion in the period from 7 August 2014 to 28 October 2014.

Since the announcement as of 6 October 2014, the following transactions have been made under the programme:

	Number of B shares	Average purchase price	Transaction value, DKK
Accumulated, last announcement	9,330,000		2,460,015,309
6 October 2014	220,000	279.56	61,503,904
7 October 2014	210,000	273.54	57,443,631
8 October 2014	235,000	266.50	62,626,654
9 October 2014	235,000	266.14	62,541,984
10 October 2014	230,000	259.90	59,777,621
Accumulated under the programme	10,460,000		2,763,909,103

With the transactions stated above, Novo Nordisk owns a total of 45,041,289 B shares of DKK 0.20, corresponding to 1.7% of the share capital, as treasury shares. The total amount of A and B shares in the company is 2,650,000,000 including treasury shares.

Novo Nordisk A/S Investor Relations Novo Allé 2880 Bagsværd Denmark Telephone: +45 4444 8888 Internet: www.novonordisk.com

CVR no: 24 25 67 90

Company announcement No 63 / 2014

Novo Nordisk expects to repurchase B shares for an amount up to DKK 15.0 billion during a 12-month period beginning 30 January 2014. As of 10 October 2014, Novo Nordisk has repurchased a total of 42,197,995 B shares equal to a transaction value of DKK 10,468,427,602.

Novo Nordisk is a global healthcare company with more than 90 years of innovation and leadership in diabetes care. The company also has leading positions within haemophilia care, growth hormone therapy and hormone replacement therapy. Headquartered in Denmark, Novo Nordisk employs approximately 40,700 employees in 75 countries, and markets its products in more than 180 countries. Novo Nordisk's B shares are listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit novonordisk.com.

## **Further information**

<i>Media:</i> Anne Margrethe Hauge	+45 4442 3450	amhg@novonordisk.com
Investors:		
Kasper Roseeuw Poulsen	+45 3079 4303	<u>krop@novonordisk.com</u>
Jannick Lindegaard Denholt	+45 3079 8519	<u>jlis@novonordisk.com</u>
Daniel Bohsen	+45 3079 6376	<u>dabo@novonordisk.com</u>
Frank Daniel Mersebach (US)	+1 609 235 8567	fdni@novonordisk.com

Novo Nordisk A/S Investor Relations Novo Allé 2880 Bagsværd Denmark Telephone:CVR+45 4444 888824 2Internet:24 2www.novonordisk.com2014Company announcement No 63 / 2014

CVR no: 24 25 67 90